Clinical Trials
3 trialsNCT06866574 2025-07-31
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Xiamen University
Phase 3 Active not recruiting
NCT00501137 2015-04-10
BCGov-01
University of British Columbia
Phase 3 Completed
NCT01512784 2012-01-19
Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults
University of Milan
Phase 3 Unknown